Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed DLBCL patients who received R2-CHOP21 in two independent phase 2 trials,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Castellino, A., Chiappella, A., LaPlant, B. R., Pederson, L. D., Gaidano, G., Macon, W. R., Inghirami, G., Reeder, C. B., Tucci, A., King, R. L., Congiu, A., Foran, J. M., Pavone, V., Rivera, C. E., Spina, M., Ansell, S. M., Cavallo, F., Molinari, A. L., Ciccone, Giovannino, Habermann, T. M., Witzig, T. E., Vitolo, U., Nowakowski, G. S.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224549/
https://ncbi.nlm.nih.gov/pubmed/30410035
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0145-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados